Abstract
A search for a suitable replacement for the central norbornyl scaffold presented in the recently disclosed novel FLAP inhibitors is herein described, as well as the SAR study performed on the endo and exo-aryl groups.
Copyright © 2012 Elsevier Ltd. All rights reserved.
MeSH terms
-
5-Lipoxygenase-Activating Protein Inhibitors / chemical synthesis*
-
5-Lipoxygenase-Activating Protein Inhibitors / pharmacokinetics
-
5-Lipoxygenase-Activating Protein Inhibitors / pharmacology
-
5-Lipoxygenase-Activating Proteins / chemistry*
-
5-Lipoxygenase-Activating Proteins / metabolism
-
Alkanes / chemical synthesis*
-
Alkanes / pharmacokinetics
-
Alkanes / pharmacology
-
Animals
-
Anti-Allergic Agents / chemical synthesis*
-
Anti-Allergic Agents / pharmacokinetics
-
Anti-Allergic Agents / pharmacology
-
Benzene Derivatives / chemical synthesis*
-
Benzene Derivatives / pharmacokinetics
-
Benzene Derivatives / pharmacology
-
Humans
-
Inhibitory Concentration 50
-
Injections, Intravenous
-
Neutrophils / drug effects
-
Neutrophils / metabolism
-
Rats
-
Stereoisomerism
-
Structure-Activity Relationship
Substances
-
5-Lipoxygenase-Activating Protein Inhibitors
-
5-Lipoxygenase-Activating Proteins
-
ALOX5AP protein, human
-
Alkanes
-
Anti-Allergic Agents
-
Benzene Derivatives